NCT02947685 · OUTCOME

Incidence of Grade 3 or Higher Adverse Events (as Graded by NCI CTCAE v 4.0)

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer · Source last updated 2026-02-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

The proportion of patient by arm that experienced grade 3 or higher adverse events will be reported

Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)

AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm A	261
Arm B	257

Source class 1

Values in proportion of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm A	0.797	Not reported	Not reported	Not reported	Not reported
Arm B	0.306	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

The proportion of patient by arm that experienced grade 3 or higher adverse events will be reported

groups

param Type

NUMBER

reporting Status

POSTED

time Frame

24 months

title

Incidence of Grade 3 or Higher Adverse Events (as Graded by NCI CTCAE v 4.0)

type

SECONDARY

unit Of Measure

proportion of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice